RecruitingPhase 2NCT07019220

Chemoablation for Low-Grade Bladder Cancer

COBRA - Chemoablation for Low Grade Bladder Cancer: A Single Arm, Prospective, Open-label, Investigator-initiated Phase 2 Study

Sponsor

Ekaterina Laukhtina

Enrollment

47 participants

Start Date

Dec 27, 2023

Study Type

INTERVENTIONAL

Conditions

Bladder (Urothelial, Transitional Cell) Cancer

Summary

The goal of this single arm, prospective, open-label, investigator-initiated Phase 2 clinical trial is to evaluate the efficacy of intravesical chemoablation in patients with low grade bladder cancer.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is testing a non-surgical treatment called chemoablation (using a chemical solution to destroy the tumor) as an alternative to surgery for people with small, low-grade, non-muscle-invasive bladder cancer that has come back. **You may be eligible if...** - You are 18 or older - You have been confirmed to have low-grade, non-muscle-invasive bladder cancer (TaLG) that has returned - Your tumors are 5 or fewer in number and the largest is 15mm or smaller - You are being considered for a bladder tumor removal procedure (TURBT) **You may NOT be eligible if...** - Your cancer is high-grade or has invaded the muscle layer - You have more than 5 bladder tumors or any single tumor larger than 15mm - You have active urinary tract infection or other bladder conditions - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.